On August 27, 2026 Oncoinvent reported that its management will give an online presentation to investors, analysts and the press at 10:00am CEST. It will be possible to submit questions during the presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presenters: CEO Oystein Soug, CFO Ramzi Amri
Time: 10:00am CEST
Webcast link: View Source
A recording of the webcast will be made available on www.oncoinvent.com after the live sending.
Highlights:
Achieved 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin
Added four new clinical sites to Oncoinvent’s Phase 2 trial
Presented positive 24-month follow-up data from Phase 1 ovarian cancer trial of Radspherin at 27th Congress of the European Society of Gynaecological Oncology (ESGO) 2026
Appointed Dr Ramzi Amri as Chief Financial Officer (CFO)
Secured new patent expanding protection for Radspherin
Post-period highlights:
Announced publication of normal tissue dosimetry results in Journal of Nuclear Medicine
Announced abstracts accepted at two major scientific conferences:
European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain (23-27 October)
European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria (17-21 October)
Oystein Soug, CEO, commented: "We entered the year with a clear focus on accelerating patient recruitment, and I am pleased to say that these efforts are delivering tangible results. Recruitment momentum accelerated significantly during the first half of the year, reinforcing our confidence in the potential of Radspherin to address a significant unmet medical need in ovarian cancer."
Key financial figures
AMOUNTS IN 1 000 NOK 1H 2026 1H 2025 FY2025
Total operating revenue 8 203 11 960 28 069
Total operating expenses (77 195) (63 978) (186 399)
Operating profit (-loss) (68 992) (52 018) (158 330)
Cash 108 839 77 412 179 670
Earnings per share (EPS) (15.20) (54.01) (125.13)
# Shares 4 478 412 962 544 1 239 249
Employees (FTEs) 42 36 44
The interim financial information has not been subject to audit
Reporting material:
Oncoinvent 1H26 report
Oncoinvent 1H26 presentation
The reporting material are also available in the Investor Relations section of the Company’s website at www.oncoinvent.com.
(Press release, Oncoinvent, AUG 27, 2026, https://www.oncoinvent.com/press-release/oncoinvent-presents-first-half-2026-results/ [SID1234670350])